Héctor Meijide1, Sonia Pértega, Iria Rodríguez-Osorio, Ángeles Castro-Iglesias, Josefa Baliñas, Guillermo Rodríguez-Martínez, Álvaro Mena, Eva Poveda. 1. aGrupo de Virología Clínica, Instituto de Investigación Biomédica de A Coruña-Complexo Hospitalario Universitario de A Coruña, Sergas, Universidade da Coruña, Coruña bServicio de Medicina Interna, Hospital Quirón cUnidad de Epidemiología Clínica y Bioestadística, Instituto de Investigación Biomédica de A Coruña-Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña dUnidad de Admisión y Documentación Clínica, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain.
Abstract
BACKGROUND: Cancer is a growing problem in persons living with HIV infection (PLWH) and hepatitis C virus (HCV) coinfection could play an additional role in carcinogenesis. Herein, all cancers in an HIV-mono and HIV/HCV-coinfected cohort were evaluated and compared to identify any differences between these two populations. METHODS: A retrospective cohort study was conducted including all cancers in PLWH between 1993 and 2014. Cancers were classified in two groups: AIDS-defining cancer (ADC) and non-AIDS-defining cancer (NADC). Cancer incidence rates were calculated and compared with that observed in the Spanish general population (GLOBOCAN, 2012), computing the standardized incidence ratios (SIRs). A competing risk approach was used to estimate the probability of cancer after HIV diagnosis. Cumulative incidence in HIV-monoinfected and HIV/HCV-coinfected patients was also compared using multivariable analysis. RESULTS: A total of 185 patients (117 HIV-monoinfected and 68 HIV/HCV) developed cancer in the 26 580 patient-years cohort, with an incidence rate of 696 cancers per 100 000 person-years, higher than in the general population (SIR = 3.8). The incidence rate of NADC in HIV/HCV-coinfected patients was 415.0 (SIR = 3.4), significantly higher than in monoinfected (377.3; SIR = 1.8). After adjustments, HIV/HCV-coinfected patients had a higher cumulative incidence of NADC than HIV-monoinfected (adjusted hazard ratio = 1.80), even when excluding hepatocellular carcinomas (adjusted hazard ratio = 1.26). CONCLUSION: PLWH have a higher incidence of NADC than the general population and HCV-coinfection is associated with a higher incidence of NADC. These data justify the need for prevention strategies in these two populations and the importance of eradicating HCV.
BACKGROUND:Cancer is a growing problem in persons living with HIV infection (PLWH) and hepatitis C virus (HCV) coinfection could play an additional role in carcinogenesis. Herein, all cancers in an HIV-mono and HIV/HCV-coinfected cohort were evaluated and compared to identify any differences between these two populations. METHODS: A retrospective cohort study was conducted including all cancers in PLWH between 1993 and 2014. Cancers were classified in two groups: AIDS-defining cancer (ADC) and non-AIDS-defining cancer (NADC). Cancer incidence rates were calculated and compared with that observed in the Spanish general population (GLOBOCAN, 2012), computing the standardized incidence ratios (SIRs). A competing risk approach was used to estimate the probability of cancer after HIV diagnosis. Cumulative incidence in HIV-monoinfected and HIV/HCV-coinfectedpatients was also compared using multivariable analysis. RESULTS: A total of 185 patients (117 HIV-monoinfected and 68 HIV/HCV) developed cancer in the 26 580 patient-years cohort, with an incidence rate of 696 cancers per 100 000 person-years, higher than in the general population (SIR = 3.8). The incidence rate of NADC in HIV/HCV-coinfectedpatients was 415.0 (SIR = 3.4), significantly higher than in monoinfected (377.3; SIR = 1.8). After adjustments, HIV/HCV-coinfectedpatients had a higher cumulative incidence of NADC than HIV-monoinfected (adjusted hazard ratio = 1.80), even when excluding hepatocellular carcinomas (adjusted hazard ratio = 1.26). CONCLUSION: PLWH have a higher incidence of NADC than the general population and HCV-coinfection is associated with a higher incidence of NADC. These data justify the need for prevention strategies in these two populations and the importance of eradicating HCV.
Authors: Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins Journal: Genes Dev Date: 2018-06-26 Impact factor: 11.361
Authors: Sarah J Willis; H Nina Kim; Chad J Achenbach; Edward R Cachay; Katerina A Christopoulos; Heidi M Crane; Ricardo A Franco; Christopher B Hurt; Mari M Kitahata; Richard D Moore; Michael J Silverberg; Phyllis C Tien; Daniel Westreich; Julia L Marcus Journal: HIV Med Date: 2021-12-23 Impact factor: 3.094
Authors: Adam Trickey; Margaret T May; M John Gill; Sophie Grabar; Janne Vehreschild; Ferdinand W N M Wit; Fabrice Bonnet; Matthias Cavassini; Sophie Abgrall; Juan Berenguer; Christoph Wyen; Peter Reiss; Katharina Grabmeier-Pfistershammer; Jodie L Guest; Leah Shepherd; Ramon Teira; Antonella d'Arminio Monforte; Julia Del Amo; Amy Justice; Dominique Costagliola; Jonathan A C Sterne Journal: Int J Cancer Date: 2020-03-12 Impact factor: 7.396